Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Audentes Therapeutics, Inc. (BOLD) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/07/2019 8-K Quarterly results
Docs: "Audentes Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
08/06/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update"
02/27/2019 8-K Quarterly results
08/07/2018 8-K Quarterly results
Docs: "Cash Position: At June 30, 2018, Audentes had cash, cash equivalents, and short-term investments of $314.4 million. Current cash, cash equivalents and short-term investments are expected to fund operations into the second half of 2020. • Research and Development Expense: Research and development expense was $26.3 million for the second quarter of 2018 compared to $18.8 million for the same period in 2017, an increase of $7.5 million. The increase in research and development expense was primarily attributable to an increase in development costs related to our AT982 program, increased headcount and related facility costs, increased internal manufacturing costs and higher stock compensation expense. Research and development expense for the second quarter includes $2.3 million of non-ca..."
05/09/2018 8-K Quarterly results
Docs: "Cash Position: At March 31, 2018, Audentes had cash, cash equivalents, and short-term investments of $326.1 million. Current cash, cash equivalents and short-term investments are planned to fund operations into the second half of 2020. • Research and Development Expenses: Research and development expenses were $19.9 million for the first quarter of 2018 compared to $14.6 million for the same period in 2017, an increase of $5.3 million. The increase in research and development expenses was primarily attributable to an increase in development costs related to our AT982 program, increased headcount and related facility costs, increased internal manufacturing costs and higher stock compensation expense, and is partially offset by a decrease in the estimated fair value of the contingent ..."
03/08/2018 8-K Quarterly results
Docs: "Cash Position: At December 31, 2017, Audentes had cash, cash equivalents, and short-term investments of $133.6 million. In January 2018, Audentes further strengthened its balance sheet with the completion of a follow-on financing, issuing 6,612,500 shares of common stock at an offering price of $35.00 per share, resulting in net proceeds of approximately $217.2 million after the deduction of underwriting discounts, commissions and estimated offering expenses. Current cash, cash equivalents and short-term investments are planned to fund operations into the second half of 2020. • Research and Development Expenses: Research and development expenses were $21.7 million for the fourth quarter of 2017 and $75.9 million for the year ended December 31, 2017, compared to $16.6 million and $48..."
11/14/2017 8-K Quarterly results
Docs: "Cash Position: As of September 30, 2017, Audentes had cash, cash equivalents and short-term investments of approximately $156.0 million. • R&D Expenses: Research and development expenses were $20.9 million for the third quarter of 2017 compared to $12.5 million for the same period in 2016, an increase of $8.4 million. The increase was primarily due to increased research and development expenses for our AT132 and AT307 programs, increases in our research and development headcount and higher facility costs as we made additional investments in our manufacturing and research facilities. For the nine months ended September 30, 2017, research and development expenses were $54.2 million compared to $32.2 million for the same period in 2016. • General and Administrative: General and ..."
08/10/2017 8-K Quarterly results
05/11/2017 8-K Form 8-K - Current report
03/09/2017 8-K Form 8-K - Current report
11/10/2016 8-K Quarterly results
Docs: "Initial Public Offering: Strengthened the balance sheet with the completion of an initial public offering in July 2016. In the IPO, Audentes issued 5.675 million shares of common stock, inclusive of the underwriters’ overallotment option, at an offering price of $15 per share, resulting in aggregate cash proceeds to the company of $75.2 million, net of underwriting discounts, commissions and offering costs. • Large-Scale Manufacturing: Successfully completed large-scale engineering runs and qualified a state-of-the-art manufacturing facility. The Audentes manufacturing facility has been designed as a multi-product facility and built to adhere to U.S. Food and Drug Administration and European Medicines Agency standards, and establishes Audentes as a leader in the science of AAV gene ..."
08/31/2016 8-K Quarterly results
Docs: "Audentes Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy